Autoimmune diseases occur when the immune system is unable to distinguish between a natural part of the body and a foreign substance. These diseases range from targeting of specific organs, to broader systemic conditions.
Current therapies for autoimmune diseases tend to be invasive and ineffective for patients, often causing severe immunogenic side effects. Immunovant is dedicated to serving this patient population by bringing novel therapies that not only treat the symptoms, but modify the course of autoimmune diseases.
Our primary investigational product candidate is IMVT-1401, a human recombinant anti-FcRn monoclonal antibody that is being developed with a focus on patient need, and may be applicable to a wide array of autoimmune diseases.